# Differentiation Induction in Acute Myelogenous Leukemia

> **NCT00175812** · PHASE1,PHASE2 · COMPLETED · sponsor: **University of Bergen** · enrollment: 24 (actual)

## Conditions studied

- Acute Myelogenous Leukemia

## Interventions

- **DRUG:** all-trans retinoic acid (ATRA)
- **DRUG:** Valproic acid
- **DRUG:** Theophyllin

## Key facts

- **NCT ID:** NCT00175812
- **Lead sponsor:** University of Bergen
- **Sponsor class:** OTHER
- **Phase:** PHASE1,PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2004-11
- **Primary completion:** 2008-05
- **Final completion:** 2009-11
- **Target enrollment:** 24 (ACTUAL)
- **Last updated:** 2015-06-24


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT00175812

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT00175812, "Differentiation Induction in Acute Myelogenous Leukemia". Retrieved via AI Analytics 2026-09-07 from https://api.ai-analytics.org/clinical/NCT00175812. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*